10:22 AM EDT, 06/27/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ) was at last look on Thursday up 2.4% after it said that Dalton Pharma Services has completed the good manufacturing practice (GMP) glass vial filling stage for cilastatin, Arch's second drug candidate for preventing acute kidney injury (AKI).

Dalton will be completing the quality control process over the next six to eight weeks which will result in the release of a "first-ever, stand-alone" cilastatin drug product to be used in a Phase II trial targeting drug toxin related AKI in hospitalized patients, a statement said.

Arch is an industry partner with a group of Canadian clinical researchers in a planned Phase II clinical trial targeting drug toxin-related AKI, which is expected to start in late 2024.

Price: 1.69, Change: +0.04, Percent Change: +2.42